Syner-G BioPharma Group acquires IMPACT


The acquisition enables Syner-G to provide deeper, broader expertise to customers

Syner-G BioPharma Group, a leading provider consultant services to pharmaceutical and biotechnology clients, announces the acquisition of Impact Pharmaceutical Services. Based in Research Triangle Park, NC, IMPACT supports the outsourced medical writing, regulatory strategy, and regulatory publishing and submission needs of biotech and pharma companies from pre-IND through post- marketing of drugs and biologics.

Both Syner-G and IMPACT have demonstrated strong track records of consistent growth and success in providing customised and highly complementary solutions to support the development of quality of life enhancing and lifesaving therapeutics. The combination will allow the companies to provide an even greater depth and breadth of expertise while delivering the highest levels of scientific rigour and customer service.

“This acquisition adds medical writing, overall drug development and regulatory strategy, and regulatory publishing and submission services to Syner-G’s capabilities which will allow us to better support our customers as they develop lifesaving and breakthrough therapeutics,” stated Prabu Nambiar, Founder and CEO of Syner-G. “The combination brings together two excellent companies with very similar organizational histories, operating philosophies, and corporate cultures.”

“We are thrilled to add IMPACT’s complementary service offering and excellent team of qualified, experienced, and dedicated employees to Syner-G,” added Binesh Prabhakar, Co- Founder and Senior Vice President of Quality Assurance & Compliance of Syner-G. “In addition, the transaction will allow Syner-G to have a significant presence in the RTP area, a fast growing biotech hub.”

Sign up for your free email newsletter